Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Aztreonam

FDA-approved product (injectable, injection), marketed as Azactam, Azactam In Plastic Container, Aztreonam and 1 more.

Registered studies
50+
Lab records
165
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Aztreonam
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Cystic fibrosis
  • Infection
  • Pneumonia
  • Pyelonephritis
  • Sepsis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Monobactams
FDA pharmacologic class
Monobactam Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DF01; FDA class Monobactam Antibacterial

Repurposing investigation

Aztreonam is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA18.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli97.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae31.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 4 of 4 lab records
  • K. pneumoniae: measured active in 34 of 161 lab records
Open Aztreonam in ChEMBL Registered studies below
Show the latest 150 of 165 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Aztreonam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)

    NCT01689207 · start 2012-09

    Registered record
    Registry ID
    NCT01689207
    Conditions
    Complicated Infection; Bacterial Infections
    Interventions
    Avibactam (AVI); Aztreonam (ATM); combination of Aztreonam - Avibactam (ATM-AVI); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-09
    Completion
    2014-12
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Infection; Bacterial Infections
    InterventionAvibactam (AVI); Aztreonam (ATM); combination of Aztreonam - Avibactam (ATM-AVI); Placebo
    PhasePhase 1
    Registry statusCompleted

  • Antibiotic Prophylaxis for Transrectal Prostate Biopsy

    NCT01659866 · start 2012-08

    Registered record
    Registry ID
    NCT01659866
    Conditions
    Infection
    Interventions
    Ciprofloxacin; trimethoprim-sulfamethoxazole; cefuroxime; ceftriaxone; gentamicin; amikacin; aztreonam; imipenem; ceftriaxone; gentamicin; amikacin; aztreonam; imipenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-08
    Completion
    2016-08
    Enrolment
    563

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    InterventionCiprofloxacin; trimethoprim-sulfamethoxazole; cefuroxime; ceftriaxone +9 more
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections

    NCT01400867 · start 2011-12

    Registered record
    Registry ID
    NCT01400867
    Conditions
    Infections, Pediatrics
    Interventions
    Ceftaroline fosamil; Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam; Cephalexin or Clindamycin or Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2011-12
    Completion
    2014-07
    Enrolment
    163

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Pediatrics
    InterventionCeftaroline fosamil; Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam; Cephalexin or Clindamycin or Linezolid
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways

    NCT01404234 · start 2011-12

    Registered record
    Registry ID
    NCT01404234
    Conditions
    Cystic Fibrosis; Pseudomonas Aeruginosa
    Interventions
    AZLI
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-12
    Completion
    2013-04
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Pseudomonas Aeruginosa
    InterventionAZLI
    PhasePhase 3
    Registry statusCompleted

  • Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients

    NCT01375036 · start 2011-08

    Registered record
    Registry ID
    NCT01375036
    Conditions
    Cystic Fibrosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-08
    Completion
    2016-12
    Enrolment
    510

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Aztreonam Lysine for Pseudomonas Infection Eradication Study

    NCT01375049 · start 2011-08

    Registered record
    Registry ID
    NCT01375049
    Conditions
    Cystic Fibrosis
    Interventions
    Aztreonam for Inhalation Solution (AZLI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-08
    Completion
    2013-05
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionAztreonam for Inhalation Solution (AZLI)
    PhasePhase 2
    Registry statusCompleted

  • Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

    NCT01313624 · start 2011-04

    Registered record
    Registry ID
    NCT01313624
    Conditions
    Bronchiectasis
    Interventions
    AZLI; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-04
    Completion
    2013-06
    Enrolment
    266

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchiectasis
    InterventionAZLI; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

    NCT01314716 · start 2011-04

    Registered record
    Registry ID
    NCT01314716
    Conditions
    Bronchiectasis
    Interventions
    AZLI; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-04
    Completion
    2013-07
    Enrolment
    274

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchiectasis
    InterventionAZLI; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies

    NCT01319253 · start 2011-03

    Registered record
    Registry ID
    NCT01319253
    Conditions
    Cystic Fibrosis; Pseudomonas Aeruginosa
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-03
    Completion
    2015-10
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Pseudomonas Aeruginosa
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis

    NCT01460836 · start 2010-04

    Registered record
    Registry ID
    NCT01460836
    Conditions
    Cystic Fibrosis
    Interventions
    Tobramycin solution for inhalation; Aztreonam lysine for inhalation
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-04
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionTobramycin solution for inhalation; Aztreonam lysine for inhalation
    PhaseNot recorded
    Registry statusCompleted

  • Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis

    NCT00805025 · start 2008-12

    Registered record
    Registry ID
    NCT00805025
    Conditions
    Bronchiectasis
    Interventions
    AZLI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-12
    Completion
    2009-10
    Enrolment
    89

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchiectasis
    InterventionAZLI
    PhasePhase 2
    Registry statusCompleted

  • Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection

    NCT00794586 · start 2008-11

    Registered record
    Registry ID
    NCT00794586
    Conditions
    Cystic Fibrosis
    Interventions
    FTI, AZLI; Placebo, AZLI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-11
    Completion
    2010-03
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionFTI, AZLI; Placebo, AZLI
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa

    NCT00712166 · start 2008-05

    Registered record
    Registry ID
    NCT00712166
    Conditions
    Cystic Fibrosis; Lung Infection; Pseudomonas Aeruginosa
    Interventions
    AZLI 75 mg three times daily (TID); Placebo three times daily (TID)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-05
    Completion
    2009-08
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Lung Infection; Pseudomonas Aeruginosa
    InterventionAZLI 75 mg three times daily (TID); Placebo three times daily (TID)
    PhasePhase 3
    Registry statusCompleted

  • Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

    NCT00424190 · start 2007-02

    Registered record
    Registry ID
    NCT00424190
    Conditions
    Bacterial Infections
    Interventions
    IV Vancomycin plus IV Aztreonam; Ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-02
    Completion
    2007-11
    Enrolment
    698

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionIV Vancomycin plus IV Aztreonam; Ceftaroline
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)

    NCT00128492 · start 2005-08

    Registered record
    Registry ID
    NCT00128492
    Conditions
    Cystic Fibrosis
    Interventions
    AZLI 75 mg two times a day (BID)/ three times a day (TID)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-08
    Completion
    2009-01
    Enrolment
    274

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionAZLI 75 mg two times a day (BID)/ three times a day (TID)
    PhasePhase 3
    Registry statusCompleted